Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.

Haematologica

Department of Internal Medicine V, Heidelberg University Hospital, Germany; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center.

Published: June 2024

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11141665	PMC
http://dx.doi.org/10.3324/haematol.2023.284346	DOI Listing

Publication Analysis

randomized phase

phase iii

iii gng

gng study

study schedules

schedules gemtuzumab

gemtuzumab ozogamicin

ozogamicin adjunct

adjunct intensive

intensive induction

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!